• search

Zydus Cadila files IND application for NME - ZYH2

Written by: Staff

New Delhi, Mar 27 (UNI) Cadila Healthcare Ltd today said it has filed an Investigational New Drug (IND) application for the New Molecular Entity, ZYH2, with the Drug Controller General of India.

The novel agent for treating diabetes has been designed and developed by Zydus Research Centre, the research wing of the Company.

'ZY H2', has displayed a unique profile in pre-clinical studies. The NME has the potential to improve insulin resistance and lower blood glucose in diabetic conditions without causing hypoglycemia. It also works favourably to lower the elevated lipid levels.

It is estimated that there are 30 to 33 million diabetics in India now, and every fourth diabetic in the world today is an Indian.

With this filing, Cadila has filed three INDs - ZYH1, ZYH and ZYH2. The NME - ZYH1 has entered phase two clinical trials.

Indians are genetically more susceptible to diabetes and the World Health Organisation (WHO) predicts the number of diabetics in India would go up to 40 million by 2010 and 74 million by 2025, making it the diabetes capital of the world.


For Daily Alerts
Get Instant News Updates
Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Oneindia sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Oneindia website. However, you can change your cookie settings at any time. Learn more